Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia
Conclusion There is no detectable increase in CV risk factors in MtF transsexuals who were treated with currently prescribed estrogenic compounds, while a slight worsening in lipid profile takes place in the FtM group, though within normal limits.
Source: Endocrinologia y Nutricion - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Endocrinology | Heart | Hormonal Therapy | Hormones | Laboratory Medicine | Nutrition | Study